scholarly journals National Breast Screening Programs across Europe

Breast Care ◽  
2019 ◽  
Vol 14 (6) ◽  
pp. 354-358 ◽  
Author(s):  
Florentia Peintinger
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Early Stage ◽  
Breast Cancer Mortality ◽  
Population Based ◽  
Quality Parameters ◽  
European Countries ◽  
The European Union ◽  
Screening Programs ◽  
National Breast

Background: Mammography screening programs in Europe revealed a 25–30% breast cancer mortality reduction in women between 50 and 74 years. Early cancer detection and less radical treatment in dedicated multidisciplinary breast centers have improved breast cancer care. Breast population-based screening (persons are individually identified and personally invited to attend screening) is intended to detect breast cancer at an early stage to enable lower mortality rates. Methods: The status of implementation of cancer screening programs among European countries, quality parameters and possible differences will be reviewed. Results: Implementation of the recommended maximum age range was adopted in most programs. Almost all the European countries established digital mammography as the method of screening instead of screen-film mammography. Inequalities in implementation of cancer screening in the European Union have been observed. Conclusion: Improvement of data quality and mortality registries linked to the screening programs are needed.

scholarly journals Breast cancer screening programmes in selected European countries and Poland

2021 ◽  
Vol 11 (7) ◽  
pp. 11-21
Author(s):  
Adam Jasiura ◽  
Izabela Dera ◽  
Karolina Szlachcic ◽  
Mateusz Gorzel ◽  
Joanna Zmonarska
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Mortality Rate ◽  
Breast Cancer Screening ◽  
Malignant Tumors ◽  
Breast Cancer Mortality ◽  
Breast Cancer Incidence ◽  
Screening Tests ◽  
The European Union ◽  
Screening Programs

Breast neoplasms are the most common malignant tumors among women. In recent years breast cancer incidence rate has increased. Due to this fact the European Union presents evidence-based guidelines on breast cancer screening and diagnosis. Recommended and commonly used screening test is mammography. The effectiveness of prophylaxis is measured by a decrease in breast cancer mortality rate. Detailed recommendations in EU member countries differ from those presented by the EU institutions. This paper compares the screening programme in Poland to screening programmes in other EU members. The evaluation considers compliance with European screening guidelines and changes in mortality rates since the introduction of the screening programs. General guidelines in Poland are close to European ones. However, some Polish health centers still use analog mammography instead of recommended digital mammography. Furthermore, mortality rate changes in Poland maintain on a constant level due to women’s reluctant participation in screening tests.

Advanced Breast Cancer and Breast Cancer Mortality in Randomized Controlled Trials on Mammography Screening

2009 ◽  
Vol 27 (35) ◽  
pp. 5919-5923 ◽  
Author(s):  
Philippe Autier ◽  
Clarisse Héry ◽  
Jari Haukka ◽  
Mathieu Boniol ◽  
Graham Byrnes
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Advanced Breast Cancer ◽  
Breast Cancer Screening ◽  
Advanced Cancer ◽  
Cancer Mortality ◽  
Breast Cancer Mortality ◽  
Advanced Breast ◽  
Published Data ◽  
National Breast

Purpose We assessed changes in advanced cancer incidence and cancer mortality in eight randomized trials of breast cancer screening. Patients and Methods Depending on published data, advanced cancer was defined as cancer ≥ 20 mm in size (four trials), stage II+ (four trials), and ≥ one positive lymph node (one trial). For each trial, we obtained the estimated relative risk (RR) and 95% CI between the intervention and control groups, for both breast cancer mortality and diagnosis of advanced breast cancer. Using a meta-regression approach, log(RR-mortality) was regressed on log(RR-advanced cancer), weighting each trial by the reciprocal of the square of the standard error of log(RR) for mortality. Results RR for advanced breast cancer ranged from 0.69 (95% CI, 0.61 to 0.78) in the Swedish Two-County Trial to 0.97 (95% CI, 0.97 to 1.25) in the Canadian National Breast Screening Study-1 (NBSS-1) trial. Log(RR)s for advanced cancer were highly predictive of log(RR)s for mortality (R2 = 0.95; P < .0001), and the linear regression curve had a slope of 1.00 (95% CI, 0.76 to 1.25) after fixing the intercept to zero. The slope changed only slightly after excluding the Two-County Trial and the Canadian NBSS-1 and NBSS-2 trials. Conclusion In trials on breast cancer screening, for each unit decrease in incidence of advanced breast cancer, there was an equal decrease in breast cancer mortality. Monitoring of incidence of advanced breast cancer may provide information on the current impact of screening on breast cancer mortality in the general population.

Breast Cancer Screening in Older Women—Current Evidence and Future Perspectives

2015 ◽  
Vol 11 (01) ◽  
pp. 34
Author(s):  
Nienke A de Glas ◽  
Gerrit-Jan Liefers ◽  
◽  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Older Women ◽  
Breast Cancer Screening ◽  
Early Stage ◽  
Developed Countries ◽  
Population Based ◽  
Current Data ◽  
Current Evidence ◽  
Strong Increase

As populations of developed countries are aging, the number of older women with breast cancer will strongly increase. Randomized controlled trials in breast cancer screening rarely included patients over the age of 68. As a consequence, there is no solid evidence for beneficial effects of breast cancer screening in older women. In a recent observational study, we showed that the implementation of screening in women aged 70–75 in the Netherlands resulted in a strong increase of the incidence of early-stage breast cancer, while the incidence of advanced stage breast cancer barely decreased. Hence, current data do not support population-based screening in women over the age of 70.

scholarly journals Breast cancer screening in average-risk women: towards personalized screening

2019 ◽  
Vol 92 (1103) ◽  
pp. 20190660 ◽  
Author(s):  
Almir GV Bitencourt ◽  
Carolina Rossi Saccarelli ◽  
Christiane Kuhl ◽  
Elizabeth A Morris
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Task Force ◽  
Early Stage ◽  
Breast Cancer Mortality ◽  
Mammographic Screening ◽  
Screening Strategy ◽  
Average Risk ◽  
Early Stage Disease

Breast cancer screening is widely recognized for reducing breast cancer mortality. The objective in screening is to diagnose asymptomatic early stage disease, thereby improving treatment efficacy. Screening recommendations have been widely debated over the past years and controversies remain regarding the optimal screening frequency, age to start screening, and age to end screening. While there are no new trials, follow-up information of randomized controlled trials has become available. The American College of Physicians recently issued a new guidance statement on screening for breast cancer in average-risk women, with similar recommendations to the U.S. Preventive Services Task Force and to European guidelines. However, these guidelines differ from those ofother American specialty societies. The variations reflect differences in the organizations’ values, the metrics used to evaluate screening results, and the differences in healthcare organization (individualized or state-organized healthcare). False-positive rates and overdiagnosis of biologically insignificant cancer are perceived as the most important potential harms associated with mammographic screening; however, there is limited evidence on their actual consequences. Most specialty societies agree that physicians should offer mammographic screening at age 40 years for average-risk women and discuss its benefits and potential harms to achieve a personalized screening strategy through a shared decision-making process.

Sign in / Sign up

Export Citation Format

Share Document